The Inflation Reduction Act of 2022 (IRA) introduces significant changes to Medicare prescription drug pricing and negotiation. The hope is that this legislation will lower healthcare costs. It will also impact how drug developers gain market access.
Takeaways for drug manufacturers
This white paper is your comprehensive guide to the IRA giving you up-to-date information on:
- Impact on drug pricing and reimbursement: Understand the new negotiation process and potential rebates for high-cost drugs.
- Strategies for market access: Learn how to navigate the evolving regulatory landscape and ensure your drugs reach patients.
- Compliance considerations: Discover key steps to ensure compliance with the new IRA regulations.
Why Certara?
Certara offers health economics and outcomes research services and strategic insights to help you develop effective drug commercialization strategies.